Refining and integrating schizophrenia pathophysiology - Relevance of the allostatic load concept

Neuroscience and Biobehavioral Reviews

Volumn 45, Issue , 2014, Pages 183-201

  Misiak, Błazej ^a   Frydecka, Dorota ^a   Zawadzki, Marcin ^a   Krefft, Maja ^a   Kiejna, Andrzej ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Allostatic load; Mediators of allostasis; Pathophysiology; Schizophrenia; Stress

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; NEUROLEPTIC AGENT; NEUROTROPHIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ALLOSTASIS; ALLOSTATIC LOAD; COGNITIVE DEFECT; COMORBIDITY; DISEASE COURSE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE RESPONSE; INFLAMMATION; LIFESPAN; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SCHIZOPHRENIA; SUBSTANCE ABUSE; ADAPTIVE BEHAVIOR; ANIMAL; BIOLOGICAL MODEL; CHRONIC DISEASE; MENTAL STRESS; PHYSIOLOGY;

ADAPTATION, PSYCHOLOGICAL; ANIMALS; CHRONIC DISEASE; HUMANS; MODELS, NEUROLOGICAL; SCHIZOPHRENIA; STRESS, PSYCHOLOGICAL;

EID: 84903783387     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2014.06.004     Document Type: Review

References (348)

1. Adriano F., Caltagirone C., Spalletta G. Hippocampal volume reduction in first-episode and chronic schizophrenia: a review and meta-analysis. Neuroscientist 2012, 18:180-200.
2. Akhondzadeh S., Tabatabaee M., Amini H., Ahmadi Abhari S.A., Abbasi S.H., Behnam B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr. Res. 2007, 90:179-185.
3. Alvarez M.J., Roura P., Foguet Q., Oses A., Sola J., Arrufat F.X. Posttraumatic stress disorder comorbidity and clinical implications in patients with severe mental illness. J. Nerv. Mental Dis. 2012, 200:549-552.
4. Anderson G., Maes M. Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects. Metab. Brain Dis. 2012, 27:113-119.
5. Anderson G., Maes M. Schizophrenia: linking prenatal infection to cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA receptor hypofunction, neurodevelopment and neuroprogression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 42:5-19.
6. Andreasson S., Allebeck P., Engstrom A., Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987, 2:1483-1486.
7. Anttila S., Illi A., Kampman O., Mattila K.M., Lehtimaki T., Leinonen E. Lack of association between two polymorphisms of brain-derived neurotrophic factor and response to typical neuroleptics. J. Neural Transm. 2005, 112:885-890.
8. Archer T., Kostrzewa R.M., Palomo T., Beninger R.J. Clinical staging in the pathophysiology of psychotic and affective disorders: facilitation of prognosis and treatment. Neurotoxicity Res. 2010, 18:211-228.
9. Arinami T., Takekoshi K., Itokawa M., Hamaguchi H., Toru M. Failure to find associations of the CA repeat polymorphism in the first intron and the Gly-63/Glu-63 polymorphism of the neurotrophin-3 gene with schizophrenia. Psychiatr. Genet. 1996, 6:13-15.
10. Arnsten A.F. Stress signalling pathways that impair prefrontal cortex structure and function. Nat. Rev. Neurosci. 2009, 10:410-422.
11. Atmaca M., Tezcan E., Kuloglu M., Ustundag B., Kirtas O. The effect of extract of ginkgo biloba addition to olanzapine on therapeutic effect and antioxidant enzyme levels in patients with schizophrenia. Psychiatry Clin. Neurosci. 2005, 59:652-656.
12. Auquier P., Lancon C., Rouillon F., Lader M. Mortality in schizophrenia. Pharmacoepidemiol. Drug Saf. 2007, 16:1308-1312.
13. Baig M.R., Navaira E., Escamilla M.A., Raventos H., Walss-Bass C. Clozapine treatment causes oxidation of proteins involved in energy metabolism in lymphoblastoid cells: a possible mechanism for antipsychotic-induced metabolic alterations. J. Psychiatr. Pract. 2010, 16:325-333.
14. Bath K.G., Schilit A., Lee F.S. Stress effects on BDNF expression: effects of age, sex, and form of stress. Neuroscience 2013, 239:149-156.
15. Beaton E.A., Simon T.J. How might stress contribute to increased risk for schizophrenia in children with chromosome 22q11.2 deletion syndrome?. J. Neurodev. Disord. 2011, 3:68-75.
16. Beckie T.M. A systematic review of allostatic load, health, and health disparities. Biol. Res. Nurs. 2012, 14:311-346.
17. Belvederi Murri M., Pariante C.M., Dazzan P., Hepgul N., Papadopoulos A.S., Zunszain P., Di Forti M., Murray R.M., Mondelli V. Hypothalamic-pituitary-adrenal axis and clinical symptoms in first-episode psychosis. Psychoneuroendocrinology 2012, 37:629-644.
18. Benros M.E., Mortensen P.B., Eaton W.W. Autoimmune diseases and infections as risk factors for schizophrenia. Ann. N.Y. Acad. Sci. 2012, 1262:56-66.
19. Bergen S.E., O'Dushlaine C.T., Ripke S., Lee P.H., Ruderfer D.M., Akterin S., Moran J.L., Chambert K.D., Handsaker R.E., Backlund L., Osby U., McCarroll S., Landen M., Scolnick E.M., Magnusson P.K., Lichtenstein P., Hultman C.M., Purcell S.M., Sklar P., Sullivan P.F. Genome-wide association study in a Swedish population yields support for greater CNV and MHC involvement in schizophrenia compared with bipolar disorder. Mol. Psychiatry 2012, 17:880-886.
20. Berk M., Conus P., Lucas N., Hallam K., Malhi G.S., Dodd S., Yatham L.N., Yung A., McGorry P. Setting the stage: from prodrome to treatment resistance in bipolar disorder. Bipolar Disord. 2007, 9:671-678.
21. Berk M., Kapczinski F., Andreazza A.C., Dean O.M., Giorlando F., Maes M., Yucel M., Gama C.S., Dodd S., Dean B., Magalhaes P.V., Amminger P., McGorry P., Malhi G.S. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci. Biobehav. Rev. 2011, 35:804-817.
22. Berk M., Malhi G.S., Gray L.J., Dean O.M. The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol. Sci. 2013, 34:167-177.
23. Beumer W., Drexhage R.C., De Wit H., Versnel M.A., Drexhage H.A., Cohen D. Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology 2012, 37:1901-1911.
24. Beumer W., Gibney S.M., Drexhage R.C., Pont-Lezica L., Doorduin J., Klein H.C., Steiner J., Connor T.J., Harkin A., Versnel M.A., Drexhage H.A. The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes. J. Leukoc. Biol. 2012, 92:959-975.
25. Bierhaus A., Humpert P.M., Nawroth P.P. NF-kappaB as a molecular link between psychosocial stress and organ dysfunction. Pediatr. Nephrol. 2004, 19:1189-1191.
26. Bilbo S.D., Schwarz J.M. Early-life programming of later-life brain and behavior: a critical role for the immune system. Front. Behav. Neurosci. 2009, 3:14.
27. Bizik G., Picard M., Nijjar R., Tourjman V., McEwen B.S., Lupien S.J., Juster R.P. Allostatic load as a tool for monitoring physiological dysregulations and comorbidities in patients with severe mental illnesses. Harv. Rev. Psychiatry 2013, 21:296-313.
28. Borges S., Gayer-Anderson C., Mondelli V. A systematic review of the activity of the hypothalamic-pituitary-adrenal axis in first episode psychosis. Psychoneuroendocrinology 2013, 38:603-611.
29. Bourdeau I., Bard C., Forget H., Boulanger Y., Cohen H., Lacroix A. Cognitive function and cerebral assessment in patients who have Cushing's syndrome. Endocrinol. Metab. Clin. North Am. 2005, 34:357-369. ix.
30. Bradley A.J., Dinan T.G. A systematic review of hypothalamic-pituitary-adrenal axis function in schizophrenia: implications for mortality. J. Psychopharmacol. 2010, 24:91-118.
31. Brady K.T., Sinha R. Co-occurring mental and substance use disorders: the neurobiological effects of chronic stress. Am. J. Psychiatr. 2005, 162:1483-1493.
32. Brown E.S. Effects of glucocorticoids on mood, memory, and the hippocampus. Treatment and preventive therapy. Ann. N.Y. Acad. Sci. 2009, 1179:41-55.
33. Burke L., Androutsos C., Jogia J., Byrne P., Frangou S. The Maudsley Early Onset Schizophrenia Study: the effect of age of onset and illness duration on fronto-parietal gray matter. Eur. Psychiatry 2008, 23:233-236.
34. Cadet J., Loft S., Olinski R., Evans M.D., Bialkowski K., Richard Wagner J., Dedon P.C., Moller P., Greenberg M.M., Cooke M.S. Biologically relevant oxidants and terminology, classification and nomenclature of oxidatively generated damage to nucleobases and 2-deoxyribose in nucleic acids. Free Radic. Res. 2012, 46:367-381.
35. Cannizzo E.S., Clement C.C., Morozova K., Valdor R., Kaushik S., Almeida L.N., Follo C., Sahu R., Cuervo A.M., Macian F., Santambrogio L. Age-related oxidative stress compromises endosomal proteostasis. Cell Rep. 2012, 2:136-149.
36. Cantor-Graae E., Nordstrom L.G., McNeil T.F. Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr. Res. 2001, 48:69-82.
37. Carpenter L.L., Gawuga C.E., Tyrka A.R., Lee J.K., Anderson G.M., Price L.H. Association between plasma IL-6 response to acute stress and early-life adversity in healthy adults. Neuropsychopharmacology 2010, 35:2617-2623.
38. Casadio P., Fernandes C., Murray R.M., Di Forti M. Cannabis use in young people: the risk for schizophrenia. Neurosci. Biobehav. Rev. 2011, 35:1779-1787.
39. Casey D.A., Rodriguez M., Northcott C., Vickar G., Shihabuddin L. Schizophrenia: medical illness, mortality, and aging. Int. J. Psychiatry Med. 2011, 41:245-251.
40. Catts V.S., Catts S.V., O'Toole B.I., Frost A.D. Cancer incidence in patients with schizophrenia and their first-degree relatives - a meta-analysis. Acta Psychiatr. Scand. 2008, 117:323-336.
41. Ceskova E., Kasparek T., Zourkova A., Prikryl R. Dexamethasone suppression test in first-episode schizophrenia. Neuro Endocrinol. Lett. 2006, 27:433-437.
42. Chen C.C., Huang T.L. Effects of antipsychotics on the serum BDNF levels in schizophrenia. Psychiatry Res. 2011, 189:327-330.
43. Chen da C., Wang J., Wang B., Yang S.C., Zhang C.X., Zheng Y.L., Li Y.L., Wang N., Yang K.B., Xiu M.H., Kosten T.R., Zhang X.Y. Decreased levels of serum brain-derived neurotrophic factor in drug-naive first-episode schizophrenia: relationship to clinical phenotypes. Psychopharmacology (Berl.) 2009, 207:375-380.
44. Chen S., Broqueres-You D., Yang G., Wang Z., Li Y., Wang N., Zhang X., Yang F., Tan Y. Relationship between insulin resistance, dyslipidaemia and positive symptom in Chinese antipsychotic-naive first-episode patients with schizophrenia. Psychiatry Res. 2013, 210:825-829.
45. Chung S., Chung H.Y., Jung J., Chang J.K., Hong J.P. Association among aggressiveness, neurocognitive function, and the Val66Met polymorphism of brain-derived neurotrophic factor gene in male schizophrenic patients. Compr. Psychiatry 2010, 51:367-372.
46. Collip D., Nicolson N.A., Lardinois M., Lataster T., van Os J., Myin-Germeys I. Daily cortisol, stress reactivity and psychotic experiences in individuals at above average genetic risk for psychosis. Psychol. Med. 2011, 41:2305-2315.
47. Contreras-Shannon V., Heart D.L., Paredes R.M., Navaira E., Catano G., Maffi S.K., Walss-Bass C. Clozapine-induced mitochondria alterations and inflammation in brain and insulin-responsive cells. PLoS ONE 2013, 8:e59012.
48. Corcoran C.M., Smith C., McLaughlin D., Auther A., Malaspina D., Cornblatt B. HPA axis function and symptoms in adolescents at clinical high risk for schizophrenia. Schizophr. Res. 2012, 135:170-174.
49. Correll C.U. Balancing efficacy and safety in treatment with antipsychotics. CNS Spectr. 2007, 12:12-20. 35.
50. Cosci F., Fava G.A. Staging of mental disorders: systematic review. Psychother. Psychosom. 2013, 82:20-34.
51. Costantini D., Marasco V., Moller A.P. A meta-analysis of glucocorticoids as modulators of oxidative stress in vertebrates. J. Comp. Physiol. B 2011, 181:447-456.
52. Das U.N. Polyunsaturated fatty acids and their metabolites in the pathobiology of schizophrenia. Prog. Neuropsychoparmacol. Biol. Psychiatry 2013, 42:122-134.
53. Dawson E., Powell J.F., Sham P.C., Nothen M., Crocq M.A., Propping P., Korner J., Rietschel M., van Os J., Wright P., et al. An association study of a neurotrophin-3 (NT-3) gene polymorphism with schizophrenia. Acta Psychiatr. Scand. 1995, 92:425-428.
54. de Almeida K.M., Moreira C.L., Lafer B. Metabolic syndrome and bipolar disorder: what should psychiatrists know?. CNS Neurosci. Ther. 2012, 18:160-166.
55. de Quervain D.J., Aerni A., Schelling G., Roozendaal B. Glucocorticoids and the regulation of memory in health and disease. Front. Neuroendocrinol. 2009, 30:358-370.
56. Dean O., Giorlando F., Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J. Psychiatry Neurosci. 2011, 36:78-86.
57. DeBattista C., Belanoff J., Glass S., Khan A., Horne R.L., Blasey C., Carpenter L.L., Alva G. Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. Biol. Psychiatry 2006, 60:1343-1349.
58. Del Giudice M., Ellis B.J., Shirtcliff E.A. The adaptive calibration model of stress responsivity. Neurosci. Biobehav. Rev. 2011, 35:1562-1592.
59. DeLisi L.E. The concept of progressive brain change in schizophrenia: implications for understanding schizophrenia. Schizophr. Bull. 2008, 34:312-321.
60. Dennison U., McKernan D., Cryan J., Dinan T. Schizophrenia patients with a history of childhood trauma have a pro-inflammatory phenotype. Psychol. Med. 2012, 42:1865-1871.
61. Di Nicola M., Cattaneo A., Hepgul N., Di Forti M., Aitchison K.J., Janiri L., Murray R.M., Dazzan P., Pariante C.M., Mondelli V. Serum and gene expression profile of cytokines in first-episode psychosis. Brain Behav. Immun. 2012, 31:90-95.
62. Dickerson F.B., Boronow J.J., Stallings C., Origoni A.E., Ruslanova I., Yolken R.H. Association of serum antibodies to herpes simplex virus 1 with cognitive deficits in individuals with schizophrenia. Arch. Gen. Psychiatry 2003, 60:466-472.
63. Dickerson F., Boronow J., Stallings C., Origoni A., Yolken R. The lymphotoxin Cys13Arg polymorphism and cognitive functioning in individuals with schizophrenia. Schizophr. Res. 2007, 89:173-176.
64. Dickerson F., Stallings C., Origoni A., Boronow J., Yolken R. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr. Res. 2007, 93:261-265.
65. Dickerson F., Stallings C., Sullens A., Origoni A., Leister F., Krivogorsky B., Yolken R. Association between cognitive functioning, exposure to herpes simplex virus type 1, and the COMT Val158Met genetic polymorphism in adults without a psychiatric disorder. Brain Behav. Immun. 2008, 22:1103-1107.
66. Dickerson F., Stallings C., Origoni A., Vaughan C., Khushalani S., Yolken R. Additive effects of elevated C-reactive protein and exposure to herpes simplex virus type 1 on cognitive impairment in individuals with schizophrenia. Schizophr. Res. 2012, 134:83-88.
67. Dietrich-Muszalska A., Kontek B., Rabe-Jablonska J. Quetiapine, olanzapine and haloperidol affect human plasma lipid peroxidation in vitro. Neuropsychobiology 2011, 63:197-201.
68. Dietrich-Muszalska A., Malinowska J., Olas B., Glowacki R., Bald E., Wachowicz B., Rabe-Jablonska J. The oxidative stress may be induced by the elevated homocysteine in schizophrenic patients. Neurochem. Res. 2012, 37:1057-1062.
69. Dinan T.G. Stress and the genesis of diabetes mellitus in schizophrenia. Br. J. Psychiatry Suppl. 2004, 47:S72-S75.
70. Djuric Z., Bird C.E., Furumoto-Dawson A., Rauscher G.H., Ruffin M.T.t., Stowe R.P., Tucker K.L., Masi C.M. Biomarkers of psychological stress in health disparities research. Open Biomark. J. 2008, 1:7-19.
71. Doruk A., Uzun O., Ozsahin A. A placebo-controlled study of extract of ginkgo biloba added to clozapine in patients with treatment-resistant schizophrenia. Int. Clin. Psychopharmacol. 2008, 23:223-227.
72. Drexhage R.C., Padmos R.C., de Wit H., Versnel M.A., Hooijkaas H., van der Lely A.J., van Beveren N., deRijk R.H., Cohen D. Patients with schizophrenia show raised serum levels of the pro-inflammatory chemokine CCL2: association with the metabolic syndrome in patients?. Schizophr. Res. 2008, 102:352-355.
73. Duke L.A., Allen D.N., Ross S.A., Strauss G.P., Schwartz J. Neurocognitive function in schizophrenia with comorbid posttraumatic stress disorder. J. Clin. Exp. Neuropsychol. 2010, 32:737-751.
74. Durany N., Michel T., Zochling R., Boissl K.W., Cruz-Sanchez F.F., Riederer P., Thome J. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr. Res. 2001, 52:79-86.
75. Dwivedi Y. Brain-derived neurotrophic factor and suicide pathogenesis. Ann. Med. 2010, 42:87-96.
76. Dwivedi Y., Rizavi H.S., Conley R.R., Roberts R.C., Tamminga C.A., Pandey G.N. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch. Gen. Psychiatry 2003, 60:804-815.
77. Eaton W.W., Pedersen M.G., Nielsen P.R., Mortensen P.B. Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disord. 2010, 12:638-646.
78. Egli M., Koob G.F., Edwards S. Alcohol dependence as a chronic pain disorder. Neurosci. Biobehav. Rev. 2012, 36:2179-2192.
79. Evans G.W., English K. The environment of poverty: multiple stressor exposure, psychophysiological stress, and socioemotional adjustment. Child Dev. 2002, 73:1238-1248.
80. Fan X., Henderson D.C., Nguyen D.D., Cather C., Freudenreich O., Evins A.E., Borba C.P., Goff D.C. Posttraumatic stress disorder, cognitive function and quality of life in patients with schizophrenia. Psychiatry Res. 2008, 159:140-146.
81. Fatemi S.H., Folsom T.D. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr. Bull. 2009, 35:528-548.
82. Fawzi M.H., Kira I.A., Fawzi M.M., Mohamed H.E., Fawzi M.M. Trauma profile in Egyptian adolescents with first-episode schizophrenia: relation to psychopathology and plasma brain-derived neurotrophic factor. J. Nerv. Mental Dis. 2013, 201:23-29.
83. Fazel S., Gulati G., Linsell L., Geddes J.R., Grann M. Schizophrenia and violence: systematic review and meta-analysis. PLoS Med. 2009, 6:e1000120.
84. Fernandez-Egea E., Bernardo M., Donner T., Conget I., Parellada E., Justicia A., Esmatjes E., Garcia-Rizo C., Kirkpatrick B. Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br. J. Psychiatry 2009, 194:434-438.
85. Fineberg A.M., Ellman L.M. Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia. Biol. Psychiatry 2013, 73:951-966.
86. Flatow J., Buckley P., Miller B.J. Meta-analysis of oxidative stress in schizophrenia. Biol. Psychiatry 2013, 74:400-409.
87. Flores B.H., Kenna H., Keller J., Solvason H.B., Schatzberg A.F. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology 2006, 31:628-636.
88. Frank M.G., Baratta M.V., Sprunger D.B., Watkins L.R., Maier S.F. Microglia serve as a neuroimmune substrate for stress-induced potentiation of CNS pro-inflammatory cytokine responses. Brain Behav. Immun. 2007, 21:47-59.
89. Fries G.R., Pfaffenseller B., Stertz L., Paz A.V., Dargel A.A., Kunz M., Kapczinski F. Staging and neuroprogression in bipolar disorder. Curr. Psychiatry Rep. 2012, 14:667-675.
90. Frydecka D., Beszlej A., Karabon L., Pawlak-Adamska E., Tomkiewicz A., Partyka A., Jonkisz A., Monika S.B., Kiejna A. The role of genetic variations of immune system regulatory molecules CD28 and CTLA-4 in schizophrenia. Psychiatry Res. 2013, 208:197-198.
91. Frydecka D., Misiak B., Beszlej J.A., Karabon L., Pawlak-Adamska E., Tomkiewicz A., Partyka A., Jonkisz A., Kiejna A. Genetic variants in transforming growth factor-beta gene (TGFB1) affect susceptibility to schizophrenia. Mol. Biol. Rep. 2013, 40:5607-5614.
92. Fuentes E., Fuentes F., Vilahur G., Badimon L., Palomo I. Mechanisms of chronic state of inflammation as mediators that link obese adipose tissue and metabolic syndrome. Mediators Inflamm. 2013, 2013:136584.
93. Fusar-Poli P., Smieskova R., Kempton M.J., Ho B.C., Andreasen N.C., Borgwardt S. Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neurosci. Biobehav. Rev. 2013, 37:1680-1691.
94. Galletly C., Van Hooff M., McFarlane A. Psychotic symptoms in young adults exposed to childhood trauma - a 20 year follow-up study. Schizophr. Res. 2011, 127:76-82.
95. Garner B., Phassouliotis C., Phillips L.J., Markulev C., Butselaar F., Bendall S., Yun Y., McGorry P.D. Cortisol and dehydroepiandrosterone-sulphate levels correlate with symptom severity in first-episode psychosis. J. Psychiatr. Res. 2011, 45:249-255.
96. George O., Le Moal M., Koob G.F. Allostasis and addiction: role of the dopamine and corticotropin-releasing factor systems. Physiol. Behav. 2012, 106:58-64.
97. Gill M., Hawi Z., O'Neill F.A., Walsh D., Straub R.E., Kendler K.S. Neurotrophin-3 gene polymorphisms and schizophrenia: no evidence for linkage or association. Psychiatr. Genet. 1996, 6:183-186.
98. Glover V. Maternal stress or anxiety in pregnancy and emotional development of the child. Br. J. Psychiatry 1997, 171:105-106.
99. Glover V., O'Connor T.G., O'Donnell K. Prenatal stress and the programming of the HPA axis. Neurosci. Biobehav. Rev. 2010, 35:17-22.
100. Gogtay N., Vyas N.S., Testa R., Wood S.J., Pantelis C. Age of onset of schizophrenia: perspectives from structural neuroimaging studies. Schizophr. Bull. 2011, 37:504-513.
101. Gonzalez-Pinto A., Mosquera F., Palomino A., Alberich S., Gutierrez A., Haidar K., Vega P., Barbeito S., Ortiz A., Matute C. Increase in brain-derived neurotrophic factor in first episode psychotic patients after treatment with atypical antipsychotics. Int. Clin. Psychopharmacol. 2010, 25:241-245.
102. Gougeon P.Y., Lourenssen S., Han T.Y., Nair D.G., Ropeleski M.J., Blennerhassett M.G. The pro-inflammatory cytokines IL-1beta and TNFalpha are neurotrophic for enteric neurons. J. Neurosci. 2013, 33:3339-3351.
103. Grande I., Magalhaes P.V., Kunz M., Vieta E., Kapczinski F. Mediators of allostasis and systemic toxicity in bipolar disorder. Physiol. Behav. 2012, 106:46-50.
104. Gratacos M., Gonzalez J.R., Mercader J.M., de Cid R., Urretavizcaya M., Estivill X. Brain-derived neurotrophic factor Val66Met and psychiatric disorders: meta-analysis of case-control studies confirm association to substance-related disorders, eating disorders, and schizophrenia. Biol. Psychiatry 2007, 61:911-922.
105. Green A.I. Treatment of schizophrenia and comorbid substance abuse: pharmacologic approaches. J. Clin. Psychiatry 2006, 67(Suppl. 7):31-35. quiz 36-37.
106. Green M.J., Matheson S.L., Shepherd A., Weickert C.S., Carr V.J. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol. Psychiatry 2011, 16:960-972.
107. Grima G., Benz B., Parpura V., Cuenod M., Do K.Q. Dopamine-induced oxidative stress in neurons with glutathione deficit: implication for schizophrenia. Schizophr. Res. 2003, 62:213-224.
108. Grubaugh A.L., Zinzow H.M., Paul L., Egede L.E., Frueh B.C. Trauma exposure and posttraumatic stress disorder in adults with severe mental illness: a critical review. Clin. Psychol. Rev. 2011, 31:883-899.
109. Gruber O., Hasan A., Scherk H., Wobrock T., Schneider-Axmann T., Ekawardhani S., Schmitt A., Backens M., Reith W., Meyer J., Falkai P. Association of the brain-derived neurotrophic factor val66met polymorphism with magnetic resonance spectroscopic markers in the human hippocampus: in vivo evidence for effects on the glutamate system. Eur. Arch. Psychiatry Clin. Neurosci. 2012, 262:23-31.
110. Guest P.C., Martins-de-Souza D., Vanattou-Saifoudine N., Harris L.W., Bahn S. Abnormalities in metabolism and hypothalamic-pituitary-adrenal axis function in schizophrenia. Int. Rev. Neurobiol. 2011, 101:145-168.
111. Guimaraes L.R., Jacka F.N., Gama C.S., Berk M., Leitao-Azevedo C.L., Belmonte de Abreu M.G., Lobato M.I., Andreazza A.C., Cereser K.M., Kapczinski F., Belmonte-de-Abreu P. Serum levels of brain-derived neurotrophic factor in schizophrenia on a hypocaloric diet. Prog. Neuropsychoparmacol. Biol. Psychiatry 2008, 32:1595-1598.
112. Gunduz-Bruce H., Szeszko P.R., Gueorguieva R., Ashtari M., Robinson D.G., Kane J.M., Bilder R.M. Cortisol levels in relation to hippocampal sub-regions in subjects with first episode schizophrenia. Schizophr. Res. 2007, 94:281-287.
113. Gunnar M.R., Wewerka S., Frenn K., Long J.D., Griggs C. Developmental changes in hypothalamus-pituitary-adrenal activity over the transition to adolescence: normative changes and associations with puberty. Dev. Psychopathol. 2009, 21:69-85.
114. Guo X., Li J., Wei Q., Fan X., Kennedy D.N., Shen Y., Chen H., Zhao J. Duration of untreated psychosis is associated with temporal and occipitotemporal gray matter volume decrease in treatment naive schizophrenia. PLoS ONE 2013, 8:e83679.
115. Gutteling B.M., de Weerth C., Buitelaar J.K. Prenatal stress and children's cortisol reaction to the first day of school. Psychoneuroendocrinology 2005, 30:541-549.
116. Hahn M.K., Wolever T.M., Arenovich T., Teo C., Giacca A., Powell V., Clarke L., Fletcher P., Cohn T., McIntyre R.S., Gomes S., Chintoh A., Remington G.J. Acute effects of single-dose olanzapine on metabolic, endocrine, and inflammatory markers in healthy controls. J. Clin. Psychopharmacol. 2013, 33:740-746.
117. Hamer M., Malan L. Psychophysiological risk markers of cardiovascular disease. Neurosci. Biobehav. Rev. 2010, 35:76-83.
118. Hapuarachchi J.R., Chalmers A.H., Winefield A.H., Blake-Mortimer J.S. Changes in clinically relevant metabolites with psychological stress parameters. Behav. Med. 2003, 29:52-59.
119. Harvey P.D. When does cognitive decline occur in the period prior to the first episode of schizophrenia?. Psychiatry (Edgmont) 2009, 6:12-14.
120. Hasnain M., Fredrickson S.K., Vieweg W.V., Pandurangi A.K. Metabolic syndrome associated with schizophrenia and atypical antipsychotics. Curr. Diabetes Rep. 2010, 10:209-216.
121. Hattori M., Nanko S. Association of neurotrophin-3 gene variant with severe forms of schizophrenia. Biochem. Biophys. Res. Commun. 1995, 209:513-518.
122. Hattori M., Kunugi H., Akahane A., Tanaka H., Ishida S., Hirose T., Morita R., Yamakawa K., Nanko S. Novel polymorphisms in the promoter region of the neurotrophin-3 gene and their associations with schizophrenia. Am. J. Med. Genet. 2002, 114:304-309.
123. He M., Deng C., Huang X.F. The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain. CNS Drugs 2013, 27:423-434.
124. Hedegaard M., Henriksen T.B., Sabroe S., Secher N.J. Psychological distress in pregnancy and preterm delivery. Br. Med. J. 1993, 307:234-239.
125. Heim C., Newport D.J., Mletzko T., Miller A.H., Nemeroff C.B. The link between childhood trauma and depression: insights from HPA axis studies in humans. Psychoneuroendocrinology 2008, 33:693-710.
126. Hinze-Selch D., Deuschle M., Weber B., Heuser I., Pollmacher T. Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight. Psychopharmacology (Berl.) 2000, 149:163-169.
127. Ho B.C., Andreasen N.C., Dawson J.D., Wassink T.H. Association between brain-derived neurotrophic factor Val66Met gene polymorphism and progressive brain volume changes in schizophrenia. Am. J. Psychiatr. 2007, 164:1890-1899.
128. Hodgson R., Wildgust H.J., Bushe C.J. Cancer and schizophrenia: is there a paradox. J. Psychopharmacol. 2010, 24:51-60.
129. Holtzman C.W., Shapiro D.I., Trotman H.D., Walker E.F. Stress and the prodromal phase of psychosis. Curr. Pharm. Des. 2012, 18:527-533.
130. Hong C.J., Yu Y.W., Lin C.H., Tsai S.J. An association study of a brain-derived neurotrophic factor Val66Met polymorphism and clozapine response of schizophrenic patients. Neurosci. Lett. 2003, 349:206-208.
131. Hor K., Taylor M. Suicide and schizophrenia: a systematic review of rates and risk factors. J. Psychopharmacol. 2010, 24:81-90.
132. Hori H., Yoshimura R., Yamada Y., Ikenouchi A., Mitoma M., Ida Y., Nakamura J. Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients. Int. Clin. Psychopharmacol. 2007, 22:21-27.
133. Huang T.L. Effects of antipsychotics on the BDNF in schizophrenia. Curr. Med. Chem. 2013, 20:345-350.
134. Huang E.J., Reichardt L.F. Neurotrophins: roles in neuronal development and function. Annu. Rev. Neurosci. 2001, 24:677-736.
135. Hulshoff Pol H.E., Kahn R.S. What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophr. Bull. 2008, 34:354-366.
136. Jansen L.M., Gispen-de Wied C.C., Kahn R.S. Selective impairments in the stress response in schizophrenic patients. Psychopharmacology (Berl.) 2000, 149:319-325.
137. Janssen I., Krabbendam L., Bak M., Hanssen M., Vollebergh W., de Graaf R., van Os J. Childhood abuse as a risk factor for psychotic experiences. Acta Psychiatr. Scand. 2004, 109:38-45.
138. Jia P., Wang L., Fanous A.H., Chen X., Kendler K.S., Zhao Z. A bias-reducing pathway enrichment analysis of genome-wide association data confirmed association of the MHC region with schizophrenia. J. Med. Genet. 2012, 49:96-103.
139. Jones A.L., Holliday E.G., Mowry B.J., McLean D.E., McGrath J.J., Pender M.P., Greer J.M. CTLA-4 single-nucleotide polymorphisms in a Caucasian population with schizophrenia. Brain Behav. Immun. 2009, 23:347-350.
140. Jones A.L., Mowry B.J., Pender M.P., Greer J.M. Immune dysregulation and self-reactivity in schizophrenia: do some cases of schizophrenia have an autoimmune basis?. Immunol. Cell Biol. 2005, 83:9-17.
141. Jonsdottir H., Opjordsmoen S., Birkenaes A.B., Simonsen C., Engh J.A., Ringen P.A., Vaskinn A., Friis S., Sundet K., Andreassen O.A. Predictors of medication adherence in patients with schizophrenia and bipolar disorder. Acta Psychiatr. Scand. 2013, 127:23-33.
142. Jonsson E., Brene S., Zhang X.R., Nimgaonkar V.L., Tylec A., Schalling M., Sedvall G. Schizophrenia and neurotrophin-3 alleles. Acta Psychiatr. Scand. 1997, 95:414-419.
143. Juster R.P., McEwen B.S., Lupien S.J. Allostatic load biomarkers of chronic stress and impact on health and cognition. Neurosci. Biobehav. Rev. 2010, 35:2-16.
144. Juster R.P., Bizik G., Picard M., Arsenault-Lapierre G., Sindi S., Trepanier L., Marin M.F., Wan N., Sekerovic Z., Lord C., Fiocco A.J., Plusquellec P., McEwen B.S., Lupien S.J. A transdisciplinary perspective of chronic stress in relation to psychopathology throughout life span development. Dev. Psychopathol. 2011, 23:725-776.
145. Kale A., Joshi S., Pillai A., Naphade N., Raju M., Nasrallah H., Mahadik S.P. Reduced cerebrospinal fluid and plasma nerve growth factor in drug-naive psychotic patients. Schizophr. Res. 2009, 115:209-214.
146. Kalmady S.V., Venkatasubramanian G., Shivakumar V., Jose D., Ravi V., Gangadhar B.N. Relationship between brain-derived neurotrophic factor and schneiderian first rank symptoms in antipsychotic-naive schizophrenia. Front. Psychiatry 2013, 4:64.
147. Kapczinski F., Vieta E., Andreazza A.C., Frey B.N., Gomes F.A., Tramontina J., Kauer-Sant'anna M., Grassi-Oliveira R., Post R.M. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci. Biobehav. Rev. 2008, 32:675-692.
148. Kapczinski F., Dias V.V., Kauer-Sant'Anna M., Frey B.N., Grassi-Oliveira R., Colom F., Berk M. Clinical implications of a staging model for bipolar disorders. Expert Rev. Neurother. 2009, 9:957-966.
149. Kapczinski F., Dal-Pizzol F., Teixeira A.L., Magalhaes P.V., Kauer-Sant'Anna M., Klamt F., Pasquali M.A., Quevedo J., Gama C.S., Post R. A systemic toxicity index developed to assess peripheral changes in mood episodes. Mol. Psychiatry 2010, 15:784-786.
150. Kapczinski F., Dal-Pizzol F., Teixeira A.L., Magalhaes P.V., Kauer-Sant'Anna M., Klamt F., Moreira J.C., de Bittencourt Pasquali M.A., Fries G.R., Quevedo J., Gama C.S., Post R. Peripheral biomarkers and illness activity in bipolar disorder. J. Psychiatr. Res. 2011, 45:156-161.
151. Kapoor A., Petropoulos S., Matthews S.G. Fetal programming of hypothalamic-pituitary-adrenal (HPA) axis function and behavior by synthetic glucocorticoids. Brain Res. Rev. 2008, 57:586-595.
152. Karatsoreos I.N., McEwen B.S. Resilience and vulnerability: a neurobiological perspective. F1000 Prime Rep. 2013, 5:13.
153. Katoh-Semba R., Wakako R., Komori T., Shigemi H., Miyazaki N., Ito H., Kumagai T., Tsuzuki M., Shigemi K., Yoshida F., Nakayama A. Age-related changes in BDNF protein levels in human serum: differences between autism cases and normal controls. Int. J. Dev. Neurosci. 2007, 25:367-372.
154. Kawashima K., Ikeda M., Kishi T., Kitajima T., Yamanouchi Y., Kinoshita Y., Okochi T., Aleksic B., Tomita M., Okada T., Kunugi H., Inada T., Ozaki N., Iwata N. BDNF is not associated with schizophrenia: data from a Japanese population study and meta-analysis. Schizophr. Res. 2009, 112:72-79.
155. Koob G.F., Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 2001, 24:97-129.
156. Koolschijn P.C., van Haren N.E., Bakker S.C., Hoogendoorn M.L., Hulshoff Pol H.E., Kahn R.S. Effects of brain-derived neurotrophic factor Val66Met polymorphism on hippocampal volume change in schizophrenia. Hippocampus 2010, 20:1010-1017.
157. Koskinen J., Lohonen J., Koponen H., Isohanni M., Miettunen J. Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr. Bull. 2010, 36:1115-1130.
158. Krebs M.O., Guillin O., Bourdell M.C., Schwartz J.C., Olie J.P., Poirier M.F., Sokoloff P. Brain derived neurotrophic factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia. Mol. Psychiatry 2000, 5:558-562.
159. Kronfol Z., Remick D.G. Cytokines and the brain: implications for clinical psychiatry. Am. J. Psychiatry 2000, 157:683-694.
160. Kuo F.C., Lee C.H., Hsieh C.H., Kuo P., Chen Y.C., Hung Y.J. Lifestyle modification and behavior therapy effectively reduce body weight and increase serum level of brain-derived neurotrophic factor in obese non-diabetic patients with schizophrenia. Psychiatry Res. 2013, 209:150-154.
161. Kyrou I., Tsigos C. Stress hormones: physiological stress and regulation of metabolism. Curr. Opin. Pharmacol. 2009, 9:787-793.
162. Laan W., Grobbee D.E., Selten J.P., Heijnen C.J., Kahn R.S., Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 2010, 71:520-527.
163. Lane H.Y., Liu Y.C., Huang C.L., Chang Y.C., Wu P.L., Lu C.T., Chang W.H. Risperidone-related weight gain: genetic and nongenetic predictors. J. Clin. Psychopharmacol. 2006, 26:128-134.
164. Lee B.H., Kim Y.K. Increased plasma brain-derived neurotropic factor, not nerve growth factor-beta, in schizophrenia patients with better response to risperidone treatment. Neuropsychobiology 2009, 59:51-58.
165. Leucht S., Burkard T., Henderson J., Maj M., Sartorius N. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr. Scand. 2007, 116:317-333.
166. Li W., Zhou N., Yu Q., Li X., Yu Y., Sun S., Kou C., Chen da C., Xiu M.H., Kosten T.R., Zhang X.Y. Association of BDNF gene polymorphisms with schizophrenia and clinical symptoms in a Chinese population. Am. J. Med. Genet. 2013, 162:538-545.
167. Lindenmayer J.P., Khan A., Kaushik S., Thanju A., Praveen R., Hoffman L., Cherath L., Valdez G., Wance D. Relationship between metabolic syndrome and cognition in patients with schizophrenia. Schizophr. Res. 2012, 142:171-176.
168. Liou Y.J., Liao D.L., Chen J.Y., Wang Y.C., Lin C.C., Bai Y.M., Yu S.C., Lin M.W., Lai I.C. Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients. Neuromol. Med. 2004, 5:243-251.
169. Lopresti A.L., Drummond P.D. Obesity and psychiatric disorders: commonalities in dysregulated biological pathways and their implications for treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 45C:92-99.
170. Lupien S.J., de Leon M., de Santi S., Convit A., Tarshish C., Nair N.P., Thakur M., McEwen B.S., Hauger R.L., Meaney M.J. Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nat. Neurosci. 1998, 1:69-73.
171. Lupien S.J., McEwen B.S., Gunnar M.R., Heim C. Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nat. Rev. Neurosci. 2009, 10:434-445.
172. MacMillan H.L., Georgiades K., Duku E.K., Shea A., Steiner M., Niec A., Tanaka M., Gensey S., Spree S., Vella E., Walsh C.A., De Bellis M.D., Van der Meulen J., Boyle M.H., Schmidt L.A. Cortisol response to stress in female youths exposed to childhood maltreatment: results of the youth mood project. Biol. Psychiatry 2009, 66:62-68.
173. Maker H.S., Weiss C., Silides D.J., Cohen G. Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates. J. Neurochem. 1981, 36:589-593.
174. Malchow B., Hasan A., Fusar-Poli P., Schmitt A., Falkai P., Wobrock T. Cannabis abuse and brain morphology in schizophrenia: a review of the available evidence. Eur. Arch. Psychiatry Clin. Neurosci. 2013, 263:3-13.
175. Malla A.K., Bodnar M., Joober R., Lepage M. Duration of untreated psychosis is associated with orbital-frontal grey matter volume reductions in first episode psychosis. Schizophr. Res. 2011, 125:13-20.
176. Mann K., Rossbach W., Muller M.J., Muller-Siecheneder F., Pott T., Linde I., Dittmann R.W., Hiemke C. Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine. Psychoneuroendocrinology 2006, 31:256-264.
177. Mansur R.B., Zugman A., Asevedo E.M., da Cunha G.R., Bressan R.A., Brietzke E. Cytokines in schizophrenia: possible role of anti-inflammatory medications in clinical and preclinical stages. Psychiatry Clin. Neurosci. 2012, 66:247-260.
178. Marchesi C., Affaticati A., Monici A., De Panfilis C., Ossola P., Tonna M. Predictors of symptomatic remission in patients with first-episode schizophrenia: a 16years follow-up study. Compr. Psychiatry 2013, 55:778-784.
179. Marshall G.D., Agarwal S.K., Lloyd C., Cohen L., Henninger E.M., Morris G.J. Cytokine dysregulation associated with exam stress in healthy medical students. Brain Behav. Immun. 1998, 12:297-307.
180. McEvoy J., Baillie R.A., Zhu H., Buckley P., Keshavan M.S., Nasrallah H.A., Dougherty G.G., Yao J.K., Kaddurah-Daouk R. Lipidomics reveals early metabolic changes in subjects with schizophrenia: effects of atypical antipsychotics. PLoS ONE 2013, 8:e68717.
181. McEwen B.S. Protective and damaging effects of stress mediators. N. Engl. J. Med. 1998, 338:171-179.
182. McEwen B.S. Mood disorders and allostatic load. Biol. Psychiatry 2003, 54:200-207.
183. McEwen B.S. Protection and damage from acute and chronic stress: allostasis and allostatic overload and relevance to the pathophysiology of psychiatric disorders. Ann. N.Y. Acad. Sci. 2004, 1032:1-7.
184. McEwen B.S. Protective and damaging effects of stress mediators: central role of the brain. Dialogues Clin. Neurosci. 2006, 8:367-381.
185. McEwen B.S., Seeman T. Protective and damaging effects of mediators of stress. Elaborating and testing the concepts of allostasis and allostatic load. Ann. N.Y. Acad. Sci. 1999, 896:30-47.
186. McEwen B.S., Stellar E. Stress and the individual. Mechanisms leading to disease. Arch. Intern. Med. 1993, 153:2093-2101.
187. McEwen B.S., Wingfield J.C. The concept of allostasis in biology and biomedicine. Horm. Behav. 2003, 43:2-15.
188. McFarlane A.C. The long-term costs of traumatic stress: intertwined physical and psychological consequences. World Psychiatry 2010, 9:3-10.
189. McIntyre R.S., Soczynska J.K., Konarski J.Z., Woldeyohannes H.O., Law C.W., Miranda A., Fulgosi D., Kennedy S.H. Should depressive syndromes be reclassified as metabolic syndrome type II?. Ann. Clin. Psychiatry 2007, 19:257-264.
190. Meisenzahl E.M., Rujescu D., Kirner A., Giegling I., Kathmann N., Leinsinger G., Maag K., Hegerl U., Hahn K., Moller H.J. Association of an interleukin-1beta genetic polymorphism with altered brain structure in patients with schizophrenia. Am. J. Psychiatry 2001, 158:1316-1319.
191. Meltzer H.Y. Clozapine: balancing safety with superior antipsychotic efficacy. Clin. Schizophr. Relat. Psychoses 2012, 6:134-144.
192. Meltzer H.Y., Massey B.W. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr. Opin. Pharmacol. 2011, 11:59-67.
193. Miljevic C., Nikolic M., Nikolic-Kokic A., Jones D.R., Niketic V., Lecic-Tosevski D., Spasic M.B. Lipid status, anti-oxidant enzyme defence and haemoglobin content in the blood of long-term clozapine-treated schizophrenic patients. Prog. Neuropsychoparmacol. Biol. Psychiatry 2010, 34:303-307.
194. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70:663-671.
195. Miller B.J., Culpepper N., Rapaport M.H., Buckley P. Prenatal inflammation and neurodevelopment in schizophrenia: a review of human studies. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 42:92-100.
196. Miller B.J., Gassama B., Sebastian D., Buckley P., Mellor A. Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2013, 73:993-999.
197. Miller B.J., Mellor A., Buckley P. Total and differential white blood cell counts, high-sensitivity C-reactive protein, and the metabolic syndrome in non-affective psychoses. Brain Behav. Immun. 2013, 31:82-89.
198. Misiak B., Frydecka D., Piotrowski P., Kiejna A. The multidimensional nature of metabolic syndrome in schizophrenia: lessons from studies of one-carbon metabolism and DNA methylation. Epigenomics 2013, 5:317-329.
199. Misiak B., Frydecka D., Slezak R., Piotrowski P., Kiejna A. Elevated homocysteine level in first-episode schizophrenia patients - the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse. Metab. Brain Dis. 2014, 10.1007/s11011-014-9534-3.
200. Mitchell A.J., Vancampfort D., Sweers K., van Winkel R., Yu W., De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders - a systematic review and meta-analysis. Schizophr. Bull. 2013, 39:306-318.
201. Mittal V.A., Orr J.M., Pelletier A., Dean D.J., Smith A., Lunsford-Avery J. Hypothalamic-pituitary-adrenal axis dysfunction in non-clinical psychosis. Psychiatry Res. 2013, 206:315-317.
202. Mondelli V., Dazzan P., Hepgul N., Di Forti M., Aas M., D'Albenzio A., Di Nicola M., Fisher H., Handley R., Marques T.R., Morgan C., Navari S., Taylor H., Papadopoulos A., Aitchison K.J., Murray R.M., Pariante C.M. Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: the role of stress and of antipsychotic treatment. Schizophr. Res. 2010, 116:234-242.
203. Mondelli V., Pariante C.M., Navari S., Aas M., D'Albenzio A., Di Forti M., Handley R., Hepgul N., Marques T.R., Taylor H., Papadopoulos A.S., Aitchison K.J., Murray R.M., Dazzan P. Higher cortisol levels are associated with smaller left hippocampal volume in first-episode psychosis. Schizophr. Res. 2010, 119:75-78.
204. Mondelli V., Cattaneo A., Belvederi Murri M., Di Forti M., Handley R., Hepgul N., Miorelli A., Navari S., Papadopoulos A.S., Aitchison K.J., Morgan C., Murray R.M., Dazzan P., Pariante C.M. Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume. J. Clin. Psychiatry 2011, 72:1677-1684.
205. Monji A., Kato T.A., Mizoguchi Y., Horikawa H., Seki Y., Kasai M., Yamauchi Y., Yamada S., Kanba S. Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 42:115-121.
206. Mueser K.T., Salyers M.P., Rosenberg S.D., Goodman L.A., Essock S.M., Osher F.C., Swartz M.S., Butterfield M.I. Interpersonal trauma and posttraumatic stress disorder in patients with severe mental illness: demographic, clinical, and health correlates. Schizophr. Bull. 2004, 30:45-57.
207. Muller N., Riedel M., Ackenheil M., Schwarz M.J. Cellular and humoral immune system in schizophrenia: a conceptual re-evaluation. World J. Biol. Psychiatry 2000, 1:173-179.
208. Muller N., Riedel M., Gruber R., Ackenheil M., Schwarz M.J. The immune system and schizophrenia. An integrative view. Ann. N. Y. Acad. Sci. 2000, 917:456-467.
209. Muller N., Riedel M., Schwarz M.J., Engel R.R. Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2005, 255:149-151.
210. Muller N., Krause D., Dehning S., Musil R., Schennach-Wolff R., Obermeier M., Moller H.J., Klauss V., Schwarz M.J., Riedel M. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr. Res. 2010, 121:118-124.
211. Muller N., Myint A.M., Krause D., Weidinger E., Schwarz M.J. Anti-inflammatory treatment in schizophrenia. Prog. Neuropsychoparmacol. Biol. Psychiatry 2013, 42:146-153.
212. Nanko S., Hattori M., Kuwata S., Sasaki T., Fukuda R., Dai X.Y., Yamaguchi K., Shibata Y., Kazamatsuri H. Neurotrophin-3 gene polymorphism associated with schizophrenia. Acta Psychiatr. Scand. 1994, 89:390-392.
213. Naoe Y., Shinkai T., Hori H., Fukunaka Y., Utsunomiya K., Sakata S., Matsumoto C., Shimizu K., Hwang R., Ohmori O., Nakamura J. No association between the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism and schizophrenia in Asian populations: evidence from a case-control study and meta-analysis. Neurosci. Lett. 2007, 415:108-112.
214. Nikolopoulou A., Kadoglou N.P. Obesity and metabolic syndrome as related to cardiovascular disease. Expert Rev. Cardiovasc. Ther. 2012, 10:933-939.
215. Nimgaonkar V.L., Zhang X.R., Brar J.S., DeLeo M., Ganguli R. Lack of association of schizophrenia with the neurotrophin-3 gene locus. Acta Psychiatr. Scand. 1995, 92:464-466.
216. Nitta M., Kishimoto T., Muller N., Weiser M., Davidson M., Kane J.M., Correll C.U. Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr. Bull. 2013, 39:1230-1241.
217. Numakawa T., Adachi N., Richards M., Chiba S., Kunugi H. Brain-derived neurotrophic factor and glucocorticoids: reciprocal influence on the central nervous system. Neuroscience 2013, 239:157-172.
218. O'Connor T.G., Ben-Shlomo Y., Heron J., Golding J., Adams D., Glover V. Prenatal anxiety predicts individual differences in cortisol in pre-adolescent children. Biol. Psychiatry 2005, 58:211-217.
219. Offidani E., Ruini C. Psychobiological correlates of allostatic overload in a healthy population. Brain Behav. Immun. 2012, 26:284-291.
220. Okahisa Y., Ujike H., Kunugi H., Ishihara T., Kodama M., Takaki M., Kotaka T., Kuroda S. Leukemia inhibitory factor gene is associated with schizophrenia and working memory function. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34:172-176.
221. Olivares J.M., Sermon J., Hemels M., Schreiner A. Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review. Ann. Gen. Psychiatry 2013, 12:32.
222. Oud M.J., Meyboom-de Jong B. Somatic diseases in patients with schizophrenia in general practice: their prevalence and health care. BMC Fam. Pract. 2009, 10:32.
223. Owens D.G. Adverse effects of antipsychotic agents. Do newer agents offer advantages?. Drugs 1996, 51:895-930.
224. Ozbey U., Tug E., Namli M. Interleukin-10 gene promoter polymorphism in patients with schizophrenia in a region of East Turkey. World J. Biol. Psychiatry 2009, 10:461-468.
225. Pacheco-Lopez G., Giovanoli S., Langhans W., Meyer U. Priming of metabolic dysfunctions by prenatal immune activation in mice: relevance to schizophrenia. Schizophr. Bull. 2013, 39:319-329.
226. Padurariu M., Ciobica A., Dobrin I., Stefanescu C. Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci. Lett. 2010, 479:317-320.
227. Pae C.U., Yoon C.H., Kim T.S., Kim J.J., Park S.H., Lee C.U., Lee S.J., Lee C., Paik I.H. Antipsychotic treatment may alter T-helper (TH) 2 arm cytokines. Int. Immunopharmacol. 2006, 6:666-671.
228. Pae C.U., Chiesa A., Porcelli S., Han C., Patkar A.A., Lee S.J., Park M.H., Serretti A., De Ronchi D. Influence of BDNF variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. Neuropsychobiology 2012, 65:1-11.
229. Papiol S., Molina V., Desco M., Rosa A., Reig S., Gispert J.D., Sanz J., Palomo T., Fananas L. Ventricular enlargement in schizophrenia is associated with a genetic polymorphism at the interleukin-1 receptor antagonist gene. Neuroimage 2005, 27:1002-1006.
230. Papiol S., Molina V., Rosa A., Sanz J., Palomo T., Fananas L. Effect of interleukin-1beta gene functional polymorphism on dorsolateral prefrontal cortex activity in schizophrenic patients. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2007, 144B:1090-1093.
231. Parikh V., Khan M.M., Mahadik S.P. Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J. Psychiatr. Res. 2003, 37:43-51.
232. Park S.W., Lee J.G., Kong B.G., Lee S.J., Lee C.H., Kim J.I., Kim Y.H. Genetic association of BDNF val66met and GSK-3beta-50T/C polymorphisms with tardive dyskinesia. Psychiatry Clin. Neurosci. 2009, 63:433-439.
233. Paul-Samojedny M., Owczarek A., Suchanek R., Kowalczyk M., Fila-Danilow A., Borkowska P., Kucia K., Kowalski J. Association study of interferon gamma (IFN-gamma) +874T/A gene polymorphism in patients with paranoid schizophrenia. J. Mol. Neurosci. 2011, 43:309-315.
234. Pedrini M., Chendo I., Grande I., Lobato M.I., Belmonte-de-Abreu P.S., Lersch C., Walz J., Kauer-Sant'anna M., Kapczinski F., Gama C.S. Serum brain-derived neurotrophic factor and clozapine daily dose in patients with schizophrenia: a positive correlation. Neurosci. Lett. 2011, 491:207-210.
235. Pedrini M., Massuda R., Fries G.R., de Bittencourt Pasquali M.A., Schnorr C.E., Moreira J.C., Teixeira A.L., Lobato M.I., Walz J.C., Belmonte-de-Abreu P.S., Kauer-Sant'Anna M., Kapczinski F., Gama C.S. Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. J. Psychiatr. Res. 2012, 46:819-824.
236. Penttila M., Jaaskelainen E., Haapea M., Tanskanen P., Veijola J., Ridler K., Murray G.K., Barnes A., Jones P.B., Isohanni M., Koponen H., Miettunen J. Association between duration of untreated psychosis and brain morphology in schizophrenia within the Northern Finland 1966 Birth Cohort. Schizophr. Res. 2010, 123:145-152.
237. Perlman W.R., Webster M.J., Kleinman J.E., Weickert C.S. Reduced glucocorticoid and estrogen receptor alpha messenger ribonucleic acid levels in the amygdala of patients with major mental illness. Biol. Psychiatry 2004, 56:844-852.
238. Perlman W.R., Webster M.J., Herman M.M., Kleinman J.E., Weickert C.S. Age-related differences in glucocorticoid receptor mRNA levels in the human brain. Neurobiol. Aging 2007, 28:447-458.
239. Phillips D.I., Jones A. Fetal programming of autonomic and HPA function: do people who were small babies have enhanced stress responses. J. Physiol. 2006, 572:45-50.
240. Piper M., Beneyto M., Burne T.H., Eyles D.W., Lewis D.A., McGrath J.J. The neurodevelopmental hypothesis of schizophrenia: convergent clues from epidemiology and neuropathology. Pediatr. Clin. North Am. 2012, 35:571-584.
241. Pirildar S., Gonul A.S., Taneli F., Akdeniz F. Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. Prog. Neuropsychoparmacol. Biol. Psychiatry 2004, 28:709-713.
242. Pollmacher T., Hinze-Selch D., Fenzel T., Kraus T., Schuld A., Mullington J. Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol. Am. J. Psychiatry 1997, 154:1763-1765.
243. Popovic V., Doknic M., Maric N., Pekic S., Damjanovic A., Miljic D., Popovic S., Miljic N., Djurovic M., Jasovic-Gasic M., Dieguez C., Casanueva F.F. Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia. Neuroendocrinology 2007, 85:249-256.
244. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 2008, 63:801-808.
245. Potvin S., Blanchet P., Stip E. Substance abuse is associated with increased extrapyramidal symptoms in schizophrenia: a meta-analysis. Schizophr. Res. 2009, 113:181-188.
246. Pruessner J.C., Dedovic K., Pruessner M., Lord C., Buss C., Collins L., Dagher A., Lupien S.J. Stress regulation in the central nervous system: evidence from structural and functional neuroimaging studies in human populations - 2008 Curt Richter Award Winner. Psychoneuroendocrinology 2010, 35:179-191.
247. Puri B.K. Brain tissue changes and antipsychotic medication. Expert Rev. Neurother. 2011, 11:943-946.
248. Qian L., Zhao J., Shi Y., Zhao X., Feng G., Xu F., Zhu S., He L. Brain-derived neurotrophic factor and risk of schizophrenia: an association study and meta-analysis. Biochem. Biophys. Res. Commun. 2007, 353:738-743.
249. Rapoport J.L., Giedd J.N., Gogtay N. Neurodevelopmental model of schizophrenia: update 2012. Mol. Psychiatry 2012, 17:1228-1238.
250. Rapp C., Bugra H., Riecher-Rossler A., Tamagni C., Borgwardt S. Effects of cannabis use on human brain structure in psychosis: a systematic review combining in vivo structural neuroimaging and post mortem studies. Curr. Pharm. Des. 2012, 18:5070-5080.
251. Raskind M.A., Peskind E.R., Wilkinson C.W. Hypothalamic-pituitary-adrenal axis regulation and human aging. Ann. N.Y. Acad. Sci. 1994, 746:327-335.
252. Reddy R. Antioxidant therapeutics for schizophrenia. Antioxidants Redox Signal. 2011, 15:2047-2055.
253. Rizos E.N., Rontos I., Laskos E., Arsenis G., Michalopoulou P.G., Vasilopoulos D., Gournellis R., Lykouras L. Investigation of serum BDNF levels in drug-naive patients with schizophrenia. Prog. Neuropsychoparmacol. Biol. Psychiatry 2008, 32:1308-1311.
254. Rizos E.N., Michalopoulou P.G., Siafakas N., Stefanis N., Douzenis A., Rontos I., Laskos E., Kastania A., Zoumpourlis V., Lykouras L. Association of serum brain-derived neurotrophic factor and duration of untreated psychosis in first-episode patients with schizophrenia. Neuropsychobiology 2010, 62:87-90.
255. Rizos E.N., Papadopoulou A., Laskos E., Michalopoulou P.G., Kastania A., Vasilopoulos D., Katsafouros K., Lykouras L. Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics. World J. Biol. Psychiatry 2010, 11:251-255.
256. Rizos E.N., Papathanasiou M., Michalopoulou P.G., Mazioti A., Douzenis A., Kastania A., Nikolaidou P., Laskos E., Vasilopoulou K., Lykouras L. Association of serum BDNF levels with hippocampal volumes in first psychotic episode drug-naive schizophrenic patients. Schizophr. Res. 2011, 129:201-204.
257. Roerig J.L., Steffen K.J., Mitchell J.E. Atypical antipsychotic-induced weight gain: insights into mechanisms of action. CNS Drugs 2011, 25:1035-1059.
258. Roiz-Santianez R., Crespo-Facorro B., Perez-Iglesias R., Pelayo-Teran J.M., Carrasco-Marin E., Mata I., Sanchez E., Leyva-Cobian F., Vazquez-Barquero J.L. Interleukin-1 receptor antagonist genotype and brain morphometry in first-episode non-affective psychosis. Psychiatry Res. 2008, 162:167-171.
259. Romagnani S. Human TH1 and TH2 subsets: regulation of differentiation and role in protection and immunopathology. Int. Arch. Allergy Immunol. 1992, 98:279-285.
260. Romero L.M., Dickens M.J., Cyr N.E. The reactive scope model - a new model integrating homeostasis, allostasis, and stress. Horm. Behav. 2009, 55:375-389.
261. Rosmond R. Role of stress in the pathogenesis of the metabolic syndrome. Psychoneuroendocrinology 2005, 30:1-10.
262. Rothermundt M., Arolt V., Bayer T.A. Review of immunological and immunopathological findings in schizophrenia. Brain Behav. Immun. 2001, 15:319-339.
263. Ruiz-Iriondo M., Salaberria K., Echeburua E. Schizophrenia: analysis and psychological treatment according to the clinical staging. Actas Esp. Psiquiatr. 2013, 41:52-59.
264. Ryan M.C., Collins P., Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am. J. Psychiatr. 2003, 160:284-289.
265. Rybakowski J.K., Borkowska A., Skibinska M., Szczepankiewicz A., Kapelski P., Leszczynska-Rodziewicz A., Czerski P.M., Hauser J. Prefrontal cognition in schizophrenia and bipolar illness in relation to Val66Met polymorphism of the brain-derived neurotrophic factor gene. Psychiatry Clin. Neurosci. 2006, 60:70-76.
266. Sawai A., Ohshige K., Kura N., Tochikubo O. Influence of mental stress on the plasma homocysteine level and blood pressure change in young men. Clin. Exp. Hypertens. 2008, 30:233-241.
267. Schatzberg A.F., Lindley S. Glucocorticoid antagonists in neuropsychiatric [corrected] disorders. Eur. J. Pharmacol. 2008, 583:358-364.
268. Schmidt L.M., Hesse M., Lykke J. The impact of substance use disorders on the course of schizophrenia - a 15-year follow-up study: dual diagnosis over 15 years. Schizophr. Res. 2011, 130:228-233.
269. Schwarz M.J., Chiang S., Muller N., Ackenheil M. T-helper-1 and T-helper-2 responses in psychiatric disorders. Brain Behav. Immun. 2001, 15:340-370.
270. Seeman T.E., Singer B.H., Rowe J.W., Horwitz R.I., McEwen B.S. Price of adaptation - allostatic load and its health consequences. MacArthur studies of successful aging. Arch. Intern. Med. 1997, 157:2259-2268.
271. Segerstrom S.C., Miller G.E. Psychological stress and the human immune system: a meta-analytic study of 30 years of inquiry. Psychol. Bull. 2004, 130:601-630.
272. Seok Jeong B., Kwon J.S., Yoon Kim S., Lee C., Youn T., Moon C.H., Yoon Kim C. Functional imaging evidence of the relationship between recurrent psychotic episodes and neurodegenerative course in schizophrenia. Psychiatry Res. 2005, 139:219-228.
273. Shevlin M., Houston J.E., Dorahy M.J., Adamson G. Cumulative traumas and psychosis: an analysis of the national comorbidity survey and the British Psychiatric Morbidity Survey. Schizophr. Bull. 2008, 34:193-199.
274. Shirts B.H., Prasad K.M., Pogue-Geile M.F., Dickerson F., Yolken R.H., Nimgaonkar V.L. Antibodies to cytomegalovirus and Herpes Simplex Virus 1 associated with cognitive function in schizophrenia. Schizophr. Res. 2008, 106:268-274.
275. Sinclair D., Tsai S.Y., Woon H.G., Weickert C.S. Abnormal glucocorticoid receptor mRNA and protein isoform expression in the prefrontal cortex in psychiatric illness. Neuropsychopharmacology 2011, 36:2698-2709.
276. Sinclair D., Webster M.J., Wong J., Weickert C.S. Dynamic molecular and anatomical changes in the glucocorticoid receptor in human cortical development. Mol. Psychiatry 2011, 16:504-515.
277. Sinclair D., Fullerton J.M., Webster M.J., Shannon Weickert C. Glucocorticoid receptor 1B and 1C mRNA transcript alterations in schizophrenia and bipolar disorder, and their possible regulation by GR gene variants. PLoS ONE 2012, 7:e31720.
278. Singh O.P., Chakraborty I., Dasgupta A., Datta S. A comparative study of oxidative stress and interrelationship of important antioxidants in haloperidol and olanzapine treated patients suffering from schizophrenia. Indian J. Psychiatry 2008, 50:171-176.
279. Sinha R., Jastreboff A.M. Stress as a common risk factor for obesity and addiction. Biol. Psychiatry 2013, 73:827-835.
280. Smelson D.A., Dixon L., Craig T., Remolina S., Batki S.L., Niv N., Owen R. Pharmacological treatment of schizophrenia and co-occurring substance use disorders. CNS Drugs 2008, 22:903-916.
281. Sommer I.E., de Witte L., Begemann M., Kahn R.S. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J. Clin. Psychiatry 2012, 73:414-419.
282. Song X., Fan X., Zhang J., Zhang W., Li X., Gao J., Harrington A., Ziedonis D., Lv L. Elevated levels of adiponectin and other cytokines in drug naive, first episode schizophrenia patients with normal weight. Schizophr. Res. 2013, 150:269-273.
283. Sotiropoulou M., Mantas C., Bozidis P., Marselos M., Mavreas V., Hyphantis T., Antoniou K. BDNF serum concentrations in first psychotic episode drug-naive schizophrenic patients: associations with personality and BDNF Val66Met polymorphism. Life Sci. 2013, 92:305-310.
284. Spalletta G., Morris D.W., Angelucci F., Rubino I.A., Spoletini I., Bria P., Martinotti G., Siracusano A., Bonaviri G., Bernardini S., Caltagirone C., Bossu P., Donohoe G., Gill M., Corvin A.P. BDNF Val66Met polymorphism is associated with aggressive behavior in schizophrenia. Eur. Psychiatry 2010, 25:311-313.
285. Spencer S.J., Tilbrook A. The glucocorticoid contribution to obesity. Stress 2011, 14:233-246.
286. Steel C., Haddock G., Tarrier N., Picken A., Barrowclough C. Auditory hallucinations and posttraumatic stress disorder within schizophrenia and substance abuse. J. Nerv. Mental Dis. 2011, 199:709-711.
287. Stefansson H., Ophoff R.A., Steinberg S., Andreassen O.A., Cichon S., Rujescu D., Werge T., Pietilainen O.P., Mors O., Mortensen P.B., Sigurdsson E., Gustafsson O., Nyegaard M., Tuulio-Henriksson A., Ingason A., Hansen T., Suvisaari J., Lonnqvist J., Paunio T., Borglum A.D., Hartmann A., Fink-Jensen A., Nordentoft M., Hougaard D., Norgaard-Pedersen B., Bottcher Y., Olesen J., Breuer R., Moller H.J., Giegling I., Rasmussen H.B., Timm S., Mattheisen M., Bitter I., Rethelyi J.M., Magnusdottir B.B., Sigmundsson T., Olason P., Masson G., Gulcher J.R., Haraldsson M., Fossdal R., Thorgeirsson T.E., Thorsteinsdottir U., Ruggeri M., Tosato S., Franke B., Strengman E., Kiemeney L.A., Melle I., Djurovic S., Abramova L., Kaleda V., Sanjuan J., de Frutos R., Bramon E., Vassos E., Fraser G., Ettinger U., Picchioni M., Walker N., Toulopoulou T., Need A.C., Ge D., Yoon J.L., Shianna K.V., Freimer N.B., Cantor R.M., Murray R., Kong A., Golimbet V., Carracedo A., Arango C., Costas J., Jonsson E.G., Terenius L., Agartz I., Petursson H., Nothen M.M., Rietschel M., Matthews P.M., Muglia P., Peltonen L., St Clair D., Goldstein D.B., Stefansson K., Collier D.A. Common variants conferring risk of schizophrenia. Nature 2009, 460:744-747.
288. Steiner J., Bernstein H.G., Schiltz K., Muller U.J., Westphal S., Drexhage H.A., Bogerts B. Immune system and glucose metabolism interaction in schizophrenia: a chicken-egg dilemma. Prog. Neuropsychopharmacol. Biol. Psychiatry 2012, 48:287-294.
289. Sterling P., Eyer J. Allostasis: a new paradigm to explain arousal pathology. Handbook of Lifestyle Stress, Cognition and Health 1988, 629-649. John Wiley and Sons, New York. S. Fisher, J. Reason (Eds.).
290. Strauss G.P., Duke L.A., Ross S.A., Allen D.N. Posttraumatic stress disorder and negative symptoms of schizophrenia. Schizophr. Bull. 2011, 37:603-610.
291. Strous R.D., Shoenfeld Y. Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. J. Autoimmun. 2006, 27:71-80.
292. Suarez-Pinilla P., Roiz-Santianez R., de la Foz V.O., Mata I., Fananas L., Brambilla P., Ruiz-Perez E., Crespo-Facorro B. BDNF Val66Met variants and brain volume changes in non-affective psychosis patients and healthy controls: a 3 year follow-up study. Prog. Neuropsychoparmacol. Biol. Psychiatry 2013, 45:201-206.
293. Suchanek R., Owczarek A., Paul-Samojedny M., Kowalczyk M., Kucia K., Kowalski J. BDNF val66met polymorphism is associated with age at onset and intensity of symptoms of paranoid schizophrenia in a Polish population. J. Neuropsychiatry Clin. Neurosci. 2013, 25:88-94.
294. Sugranyes G., Thompson J.L., Corcoran C.M. HPA-axis function, symptoms, and medication exposure in youths at clinical high risk for psychosis. J. Psychiatr. Res. 2012, 46:1389-1393.
295. Sun S., Wang F., Wei J., Cao L.Y., Qi L.Y., Xiu M.H., Chen S., Li X.H., Kosten T.A., Kosten T.R., Zhang X.Y. Association between interleukin-6 receptor polymorphism and patients with schizophrenia. Schizophr. Res. 2008, 102:346-347.
296. Sun S., Wang F., Wei J., Cao L.Y., Wu G.Y., Lu L., Kosten T.A., Kosten T.R., Zhang X.Y. Association between interleukin-3 receptor alpha polymorphism and schizophrenia in the Chinese population. Neurosci. Lett. 2008, 440:35-37.
297. Sun M.M., Yang L.M., Wang Y., Feng X., Cui K.Y., Liu L.F., Chen Z.Y. BDNF Val66Met polymorphism and anxiety/depression symptoms in schizophrenia in a Chinese Han population. Psychiatr. Genet. 2013, 23:124-129.
298. Szeszko P.R., Lipsky R., Mentschel C., Robinson D., Gunduz-Bruce H., Sevy S., Ashtari M., Napolitano B., Bilder R.M., Kane J.M., Goldman D., Malhotra A.K. Brain-derived neurotrophic factor val66met polymorphism and volume of the hippocampal formation. Mol. Psychiatry 2005, 10:631-636.
299. Takahashi T., Suzuki M., Tsunoda M., Kawamura Y., Takahashi N., Tsuneki H., Kawasaki Y., Zhou S.Y., Kobayashi S., Sasaoka T., Seto H., Kurachi M., Ozaki N. Association between the brain-derived neurotrophic factor Val66Met polymorphism and brain morphology in a Japanese sample of schizophrenia and healthy comparisons. Neurosci. Lett. 2008, 435:34-39.
300. Tan Y.L., Zhou D.F., Zhang X.Y. Decreased plasma brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophr. Res. 2005, 74:263-270.
301. Tandon R., Halbreich U. The second-generation 'atypical' antipsychotics: similar improved efficacy but different neuroendocrine side effects. Psychoneuroendocrinology 2003, 28(Suppl. 1):1-7.
302. Tourjman V., Kouassi E., Koue M.E., Rocchetti M., Fortin-Fournier S., Fusar-Poli P., Potvin S. Antipsychotics' effects on blood levels of cytokines in schizophrenia: a meta-analysis. Schizophr. Res. 2013, 151:43-47.
303. Trautman P.D., Meyer-Bahlburg H.F., Postelnek J., New M.I. Effects of early prenatal dexamethasone on the cognitive and behavioral development of young children: results of a pilot study. Psychoneuroendocrinology 1995, 20:439-449.
304. Tsai A., Liou Y.J., Hong C.J., Wu C.L., Tsai S.J., Bai Y.M. Association study of brain-derived neurotrophic factor gene polymorphisms and body weight change in schizophrenic patients under long-term atypical antipsychotic treatment. Neuromolecular Med. 2011, 13:328-333.
305. Valdez G.R., Koob G.F. Allostasis and dysregulation of corticotropin-releasing factor and neuropeptide Y systems: implications for the development of alcoholism. Pharmacology. Biochem. Behav. 2004, 79:671-689.
306. Van Craenenbroeck K., De Bosscher K., Vanden Berghe W., Vanhoenacker P., Haegeman G. Role of glucocorticoids in dopamine-related neuropsychiatric disorders. Mol. Cell. Endocrinol. 2005, 245:10-22.
307. van Haren N.E., Hulshoff Pol H.E., Schnack H.G., Cahn W., Mandl R.C., Collins D.L., Evans A.C., Kahn R.S. Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study. Neuropsychopharmacology 2007, 32:2057-2066.
308. Vargas H.E., Gama C.S., Andreazza A.C., Medeiros D., Stertz L., Fries G., Palha J., Cereser K.M., Berk M., Kapczinski F., Belmonte-de-Abreu P.S. Decreased serum neurotrophin 3 in chronically medicated schizophrenic males. Neurosci. Lett. 2008, 440:197-201.
309. Vega J.A., Garcia-Suarez O., Hannestad J., Perez-Perez M., Germana A. Neurotrophins and the immune system. J. Anat. 2003, 203:1-19.
310. Venkatasubramanian G., Chittiprol S., Neelakantachar N., Shetty T., Gangadhar B.N. Effect of antipsychotic treatment on insulin-like growth factor-1 and cortisol in schizophrenia: a longitudinal study. Schizophr. Res. 2010, 119:131-137.
311. Victoriano M., de Beaurepaire R., Naour N., Guerre-Millo M., Quignard-Boulange A., Huneau J.F., Mathe V., Tome D., Hermier D. Olanzapine-induced accumulation of adipose tissue is associated with an inflammatory state. Brain Res. 2010, 1350:167-175.
312. Vieta E., Popovic D., Rosa A.R., Sole B., Grande I., Frey B.N., Martinez-Aran A., Sanchez-Moreno J., Balanza-Martinez V., Tabares-Seisdedos R., Kapczinski F. The clinical implications of cognitive impairment and allostatic load in bipolar disorder. Eur. Psychiatry 2013, 28:21-29.
313. von Kanel R., Dimsdale J.E., Patterson T.L., Grant I. Acute procoagulant stress response as a dynamic measure of allostatic load in Alzheimer caregivers. Ann. Behav. Med. 2003, 26:42-48.
314. Walker E.F., Diforio D. Schizophrenia: a neural diathesis-stress model. Psychol. Rev. 1997, 104:667-685.
315. Walker E., Mittal V., Tessner K. Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia. Annu. Rev. Clin. Psychol. 2008, 4:189-216.
316. Walker E.F., Trotman H.D., Pearce B.D., Addington J., Cadenhead K.S., Cornblatt B.A., Heinssen R., Mathalon D.H., Perkins D.O., Seidman L.J., Tsuang M.T., Cannon T.D., McGlashan T.H., Woods S.W. Cortisol levels and risk for psychosis: initial findings from the North American prodrome longitudinal study. Biol. Psychiatry 2013, 74:410-417.
317. Walss-Bass C., Weintraub S.T., Hatch J., Mintz J., Chaudhuri A.R. Clozapine causes oxidation of proteins involved in energy metabolism: a possible mechanism for antipsychotic-induced metabolic alterations. Int. J. Neuropsychopharmacol. 2008, 11:1097-1104.
318. Watanabe Y., Nunokawa A., Kaneko N., Someya T. Meta-analysis of case-control association studies between the C270T polymorphism of the brain-derived neurotrophic factor gene and schizophrenia. Schizophr. Res. 2007, 95:250-252.
319. Watanabe Y., Nunokawa A., Someya T. Association of the BDNF C270T polymorphism with schizophrenia: updated meta-analysis. Psychiatry Clin. Neurosci. 2013, 67:123-125.
320. Webster M.J., Knable M.B., O'Grady J., Orthmann J., Weickert C.S. Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Mol. Psychiatry 2002, 7:985-994. 924.
321. Wu X., Huang Z., Wu R., Zhong Z., Wei Q., Wang H., Diao F., Wang J., Zheng L., Zhao J., Zhang J. The comparison of glycometabolism parameters and lipid profiles between drug-naive, first-episode schizophrenia patients and healthy controls. Schizophr. Res. 2013, 150:157-162.
322. Xiong P., Zeng Y., Wan J., Xiaohan D.H., Tan D., Lu J., Xu F., Li H.Y., Zhu Z., Ma M. The role of NGF and IL-2 serum level in assisting the diagnosis in first episode schizophrenia. Psychiatry Res. 2011, 189:72-76.
323. Xiu M.H., Hui L., Dang Y.F., Hou T.D., Zhang C.X., Zheng Y.L., Chen da C., Kosten T.R., Zhang X.Y. Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics. Prog. Neuropsychoparmacol. Biol. Psychiatry 2009, 33:1508-1512.
324. Xu M.Q., St Clair D., Ott J., Feng G.Y., He L. Brain-derived neurotrophic factor gene C-270T and Val66Met functional polymorphisms and risk of schizophrenia: a moderate-scale population-based study and meta-analysis. Schizophr. Res. 2007, 91:6-13.
325. Xu M.Q., St Clair D., Feng G.Y., Lin Z.G., He G., Li X., He L. BDNF gene is a genetic risk factor for schizophrenia and is related to the chlorpromazine-induced extrapyramidal syndrome in the Chinese population. Pharmacogenet. Genomics 2008, 18:449-457.
326. Xu M., Li S., Xing Q., Gao R., Feng G., Lin Z., St Clair D., He L. Genetic variants in the BDNF gene and therapeutic response to risperidone in schizophrenia patients: a pharmacogenetic study. Eur. J. Hum. Genet. 2010, 18:707-712.
327. Yang Y.K., Nelson L., Kamaraju L., Wilson W., McEvoy J.P. Nicotine decreases bradykinesia-rigidity in haloperidol-treated patients with schizophrenia. Neuropsychopharmacology 2002, 27:684-686.
328. Yang Y., Bazhin A.V., Werner J., Karakhanova S. Reactive oxygen species in the immune system. Int. Rev. Immunol. 2013, 32:249-270.
329. Yoshimura R., Ueda N., Hori H., Ikenouchi-Sugita A., Umene-Nakano W., Nakamura J. Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients. World J. Biol. Psychiatry 2010, 11:256-261.
330. Zai G.C., Zai C.C., Chowdhury N.I., Tiwari A.K., Souza R.P., Lieberman J.A., Meltzer H.Y., Potkin S.G., Muller D.J., Kennedy J.L. The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain. Prog. Neuropsychoparmacol. Biol. Psychiatry 2012, 39:96-101.
331. Zakharyan R., Petrek M., Arakelyan A., Mrazek F., Atshemyan S., Boyajyan A. Interleukin-6 promoter polymorphism and plasma levels in patients with schizophrenia. Tissue Antigens 2012, 80:136-142.
332. Zammit S., Allebeck P., Andreasson S., Lundberg I., Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. Br. Med. J. 2002, 325:1199.
333. Zarkovic M., Ignjatovic S., Dajak M., Ciric J., Beleslin B., Savic S., Stojkovic M., Bulat P., Trbojevic B. Cortisol response to ACTH stimulation correlates with blood interleukin 6 concentration in healthy humans. Eur. J. Endocrinol. 2008, 159:649-652.
334. Zhang X.Y., Zhou D.F., Su J.M., Zhang P.Y. The effect of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia. J. Clin. Psychopharmacol. 2001, 21:85-88.
335. Zhang X.Y., Zhou D.F., Zhang P.Y., Wu G.Y., Su J.M., Cao L.Y. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. J. Clin. Psychiatry 2001, 62:878-883.
336. Zhang X.Y., Zhou D.F., Cao L.Y., Wu G.Y., Shen Y.C. Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics. Neuropsychopharmacology 2005, 30:1532-1538.
337. Zhang X.Y., Tan Y.L., Cao L.Y., Wu G.Y., Xu Q., Shen Y., Zhou D.F. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr. Res. 2006, 81:291-300.
338. Zhang X.Y., Tan Y.L., Zhou D.F., Cao L.Y., Wu G.Y., Xu Q., Shen Y., Haile C.N., Kosten T.A., Kosten T.R. Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics. J. Psychiatr. Res. 2007, 41:997-1004.
339. Zhang X.Y., Zhou D.F., Wu G.Y., Cao L.Y., Tan Y.L., Haile C.N., Li J., Lu L., Kosten T.A., Kosten T.R. BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia. Neuropsychopharmacology 2008, 33:2200-2205.
340. Zhang X.Y., Chen da C., Xiu M.H., Haile C.N., Luo X., Xu K., Zhang H.P., Zuo L., Zhang Z., Zhang X., Kosten T.A., Kosten T.R. Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls. Hum. Genet. 2012, 131:1187-1195.
341. Zhang X.Y., Chen da C., Xiu M.H., Tang W., Zhang F., Liu L., Chen Y., Liu J., Yao J.K., Kosten T.A., Kosten T.R. Plasma total antioxidant status and cognitive impairments in schizophrenia. Schizophr. Res. 2012, 139:66-72.
342. Zhang X.Y., Zhou D.F., Shen Y.C., Zhang P.Y., Zhang W.F., Liang J., Chen da C., Xiu M.H., Kosten T.A., Kosten T.R. Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia. Neuropharmacology 2012, 62:1928-1934.
343. Zhang J.P., Lencz T., Geisler S., DeRosse P., Bromet E.J., Malhotra A.K. Genetic variation in BDNF is associated with antipsychotic treatment resistance in patients with schizophrenia. Schizophr. Res. 2013, 146:285-288.
344. Zhang X.Y., Chen da C., Xiu M.H., Tan Y.L., Yang F.D., Zhang L.Y., Haile C.N., Kosten T.R. Clinical symptoms and cognitive impairment associated with male schizophrenia relate to plasma manganese superoxide dismutase activity: a case-control study. J. Psychiatr. Res. 2013, 47:1049-1053.
345. Zhang X.Y., Chen da C., Xiu M.H., Yang F.D., Tan Y.L., He S., Kosten T.A., Kosten T.R. Thioredoxin, a novel oxidative stress marker and cognitive performance in chronic and medicated schizophrenia versus healthy controls. Schizophr. Res. 2013, 143:301-306.
346. Zhang X.Y., Chen D.C., Xiu M.H., Yang F.D., Tan Y., Luo X., Zuo L., Kosten T.A., Kosten T.R. Cognitive function, plasma MnSOD Activity, and MnSOD Ala-9Val polymorphism in patients with schizophrenia and normal controls. Schizophr. Bull. 2013, 40:592-601.
347. Zhang X.Y., Tang W., Xiu M.H., Chen da C., Yang F.D., Tan Y.L., Wang Z.R., Zhang F., Liu J., Liu L., Chen Y., Wen N., Kosten T.R. Interleukin 18 and cognitive impairment in first episode and drug naive schizophrenia versus healthy controls. Brain Behav. Immun. 2013, 32:105-111.
348. Zintzaras E. Brain-derived neurotrophic factor gene polymorphisms and schizophrenia: a meta-analysis. Psychiatr. Genet. 2007, 17:69-75.